✦ LIBER ✦

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

✍ Scribed by Druker, Brian J

Book ID: 110067209
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 134 KB
Volume: 21
Category: Article
ISSN: 0950-9232
DOI: 10.1038/sj.onc.1206081

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Protein kinase CK2α is a target for the

Protein kinase CK2α is a target for the Abl and Bcr–Abl tyrosine kinases

✍ Hériché, Jean-Karim; Chambaz, Edmond M 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 525 KB

Effects of a selective inhibitor of the

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

✍ Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Sha 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 617 KB

Bruton's tyrosine kinase is not essentia

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells

✍ MacPartlin, M; Smith, A M; Druker, B J; Honigberg, L A; Deininger, M W 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 370 KB

Inhibition of Abl tyrosine kinase enhanc

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr–Abl transformed cells via the alteration of signaling complex and the receptor turnover

✍ Koch, A; Scherr, M; Breyer, B; Mancini, A; Kardinal, C; Battmer, K; Eder, M; Tam 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 591 KB

Favorable therapeutic index of a p210BCR

Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

✍ Bernd Kasper; Stefan Fruehauf; Bernd Schiedlmeier; Elisabeth Buchdunger; Anthony 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 170 KB

Structural modeling of V299L and E459K B

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

✍ Dongho Kim; Dong-Wook Kim; Byung-Sik Cho; Hyun-Gyung Goh; Soo-Hyun Kim; Wan-Seok 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 592 KB

Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with differ